Trial Profile
A Phase 1/2a Blinded, Placebo-Controlled Study to Assess the Safety, Tolerability, and Dose-range Finding of Multiple Ascending Doses of ISIS 598769 Administered Subcutaneously to Adult Patients With Myotonic Dystrophy Type 1
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Mar 2023
Price :
$35
*
At a glance
- Drugs Baliforsen (Primary)
- Indications Myotonic dystrophy
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 01 Mar 2023 Results assessing safety of baliforsen in patients with myotonic dystrophy type 1 published in the Lancet Neurology.
- 02 Nov 2016 Status changed from active, no longer recruiting to completed.
- 16 Sep 2016 Status changed from recruiting to active, no longer recruiting.